Excessive Dialysis Product Pricing: Adcock Ingram Referred

Original Article by Tamar Kahn | Business Day | 4 June 2026

The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.

The excessive Dialysis Product Pricing case targets Adcock Ingram, with a possible 10% turnover penalty and wider renal care cost impacts.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Thembisile Xulu Named New Health Director-General

Dr Thembisile Xulu is the new health Director-General, inheriting a strained department, healthcare-worker shortages and NHI litigation.

Read more...

Gauteng Nurse Shortage Deepens, Threatening NHI Rollout

Gauteng is losing 100 nurses a month and needs R5.7bn to fill a 16,000-post gap. This shortage now flagged as a key risk to the NHI rollout.

Read more...

Medical Schemes Should Be Allowed to Offer Low-Cost Benefit Options

Regulation, not demand, blocks affordable cover: medical schemes should be allowed to offer low-cost benefit options (LCBOs) now.

Read more...